Recursion Pharmaceuticals Reports Wider Q1 Loss Amid Higher Costs, Revenue Rises
09:20 AM EDT, 05/12/2021 (MT Newswires) -- Recursion Pharmaceuticals (RXRX) said Wednesday its Q1 net loss widened to $1.33 per diluted share from $0.85 a year ago after its operating costs increased to $33 million from $18.4 million.
Revenue totaled $2.6 million in the quarter ended March 31, up from $60,000 a year ago.
Cash and cash equivalents stood at $214.1 million as of the end of March versus $262.1 million as of Dec. 31, according to the drugmaker.
Analyst estimates weren't available.
Price: 22.70, Change: +0.04, Percent Change: +0.18